ROR2 and cancer: The up-regulation of ROR2 have been described in osteosarcoma [8], squamous cell carcinoma [9], non-small cell lung carcinoma [10], pancreatic ductal adenocarcinoma [11], renal cell carcinoma [12], papillary thyroid carcinoma [13], leukemia [14], gastrointestinal cancer [15], and cancers from the prostate [16], head and neck [17], ovarian [18, 19], breast [20], and cervix [21].